Alice C. Harnden

Alice C. Harnden

Auto-generated profile, based on publicly available information

Alice C. Harnden

Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Coordination Chemistry Reviews
Verified
Journal Article
Open access
AHAlice C. Harnden
Alice C. Harnden
DPDavid Parker
David Parker
Nicola J. RogersNicola J. Rogers
Nicola J. Rogers

10 July 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
KMKevin Mason
Kevin Mason
AHAlice C. Harnden
Alice C. Harnden
CPConnor W. Patrick
Connor W. Patrick
APAdeline W. J. Poh
Adeline W. J. Poh
SBStepan Sergeevich Batsanov
Stepan Sergeevich Batsanov
DPDavid Parker
David Parker
Crystallographic, emission and NMR studies of a series of C3-symmetric, nine-coordinate substituted pyridyl triazacyclononane Yb(III) and Eu(III) complexes reveal the impact of local solvation and ligand dipolar polarisability on ligand field strength, leading to dramatic variations in pseudocontact NMR shifts and emission spectral profiles, giving new guidance for responsive NMR and spectral probe design.

22 May 2017 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
KFKatie‐Louise N. A. Finney
Katie‐Louise N. A. Finney
AHAlice C. Harnden
Alice C. Harnden
Nicola J. RogersNicola J. Rogers
Nicola J. Rogers
PSP. Kanthi Senanayake
P. Kanthi Senanayake
ABAndrew M. Blamire
Andrew M. Blamire
DPDavid Parker
David Parker

3 June 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ODOwen A. Davis
Owen A. Davis
KCKwai-Ming J. Cheung
Kwai-Ming J. Cheung
ABAlfie Brennan
Alfie Brennan
MLMatthew G. Lloyd
Matthew G. Lloyd
MRMatthew J. Rodrigues
Matthew J. Rodrigues
SHSwen Hoelder
Swen Hoelder
To identify new chemical series with enhanced binding affinity to the BTB domain of B-cell lymphoma 6 protein, we targeted a subpocket adjacent to Val18. With no opportunities for strong polar interactions, we focused on attaining close shape complementarity by ring fusion onto our quinolinone lead series. Following exploration of different sized rings, we identified a conformationally restricted core which optimally filled the available space, leading to potent BCL6 inhibitors. Through X-ray structure-guided design, combined with efficient synthetic chemistry to make the resulting novel core structures, a >300-fold improvement in activity was obtained by the addition of seven heavy atoms.

29 May 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
AHAlice C. Harnden
Alice C. Harnden
ESElizaveta A. Suturina
Elizaveta A. Suturina
ABAndrei S. Batsanov
Andrei S. Batsanov
PSP. Kanthi Senanayake
P. Kanthi Senanayake
Mark Alexander FoxMark Alexander Fox
Mark Alexander Fox
DPDavid Parker
David Parker

2 June 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RHRosemary Huckvale
Rosemary Huckvale
AHAlice C. Harnden
Alice C. Harnden
KCKwai-Ming J. Cheung
Kwai-Ming J. Cheung
OPOlivier A. Pierrat
Olivier A. Pierrat
RTRachel Talbot
Rachel Talbot
SHSwen Hoelder
Swen Hoelder
The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader CCT369260 to CCT373566, a highly potent probe suitable for sustained depletion of BCL6 in vivo. We observed a sharp degradation SAR, where subtle structural changes conveyed the ability to induce degradation of BCL6. CCT373566 showed modest in vivo efficacy in a lymphoma xenograft mouse model following oral dosing.